Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224068 · ClinicalTrials.gov registry record · Phase 4
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT00224068 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 180 participants.
The verdict
NCT00224068, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.
Interventions
- DRUG Sodium ferric gluconate, ferrous sulfate, standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2002-05 |
| Est. Completion | 2003-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224068
The ClinicalTrials.gov registry entry for NCT00224068 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium ferric gluconate, ferrous sulfate, standard of care is the first listed.
NCT00224068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224068 about?
NCT00224068 is a clinical study titled "Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy". This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.
What is the current status of trial NCT00224068?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2002-05. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00224068?
The interventions under investigation include: Sodium ferric gluconate, ferrous sulfate, standard of care (DRUG).
Who is sponsoring clinical trial NCT00224068?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.